Be Familiar With the New COVID-19 MAb, Bebtelovimab
Bebtelovimab will be a new COVID-19 monoclonal antibody (MAb).
The Omicron variant limits OUTpatient MAb treatment options to sotrovimab. Now bebtelovimab is another choice for COVID-19 patients who are at high risk of severe illness (diabetes, etc).
Similar to sotrovimab, bebtelovimab is for adults...or kids age 12 and up who weigh 40 kg or more...and is provided at no cost.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote